Quantcast

Latest Thalidomide Stories

2008-09-05 00:00:26

By Sadie Gray A cancer sufferer whose primary care trust refused to pay for a drug which could extend his life by up to three years has launched an "end of the road" legal challenge to the decision. If Colin Ross continues to be denied the drug, Revlimid, he will die within a few months, experts say. His lawyers told the High Court yesterday that he was the victim of a postcode lottery. Mr Ross, 55, said his doctors had requested funding for up to four courses of Revlimid at 5,000 a...

2008-08-22 18:00:43

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute, is leading the Phase 1 / 2, multicenter, randomized,...

2008-08-06 00:00:38

By CHRIS MALLETT A Teenage music-lover who has been treated for cancer for nearly six years has taken singing lessons with an international gospel choir, thanks to a children's charity. Alex Cooper, now 16, was told he had between six and 12 months to live when he was diagnosed with a brain tumour in August 2002. But, with the help of a trial form of chemotherapy, he was given the all-clear by doctors two years ago. The cancer and its treatments gave him a poor short-term memory,...

2008-07-28 15:01:01

Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients. Velcade would see considerable uptake if the drug is approved in the first-line setting, due to its proven activity and favorable safety profile compared to current treatment regimens. Velcade (bortezomib; Takeda/Johnson & Johnson) has received a positive opinion from the EU Committee for...

2008-07-11 12:01:05

Proteolix has started patient dosing in a Phase Ib clinical trial to evaluate the safety and efficacy of Proteolix's lead anticancer agent, carfilzomib, in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. The Phase Ib clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone on a 28 day treatment cycle. Lenalidomide in combination with dexamethasone is...

2008-07-10 09:01:29

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 1b clinical trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer agent, carfilzomib (PR-171), in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Carfilzomib selectively blocks proteasome activity, causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated...

2008-06-24 02:30:28

New Indication Provides Treatment-Free Interval As an Option Media: International Myeloma Foundation Peggy Frank, 818-735-3591 Logo: http://myeloma.org/ The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded the decision by the US Food and Drug Administration (FDA) to expand the benefits of VELCADE(R) (bortezomib) for injection to a wider range of...

2008-06-17 03:00:38

Celgene Corporation David Gryska, 908-673-9059 Sr. Vice President and Chief Financial Officer or Brian P. Gill, 908-673-9530 Vice President, Corporate Communications Data from the ECOG E4A03 and SWOG 0232 studies were reported at a Satellite Symposium and showed that newly diagnosed multiple myeloma patients who are eligible for a transplant, obtain better outcomes when treated with REVLIMID (lenalidomide) plus dexamethasone. The data were presented by Dr A. Stewart, from the Mayo...

2008-06-16 12:00:11

Vion Pharmaceuticals has reported positive data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine in elderly patients with acute myelogenous leukemia and high-risk myelodysplastic syndromes. The company presented the data in a subset of 26 patients with high-risk myelodysplastic syndromes (MDS) by French-American-British Group criteria. The median age of the patients in the subset was 71 years (range of 59-82 years). Approximately 12 patients were diagnosed...

2008-06-14 12:00:24

Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced a significant survival gain regardless of the number of prior therapies they had received. The results showed that not only was the use of REVLIMID and dexamethasone associated with a...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.